No black box warning on record for Fulvestrant

As of the latest FDA labeling reviewed, Fulvestrant (FULVESTRANT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Fulvestrant medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. ( 5.1 ) Increased Exposure in Patients with Hepatic Impairment: Use a 250 mg dose for patients with moderate hepatic impairment. ( 2.2 , 5.2 , 8.6 ) Injection Site Reaction: Use caution while administering Fulvestrant Injection at the dorsogluteal injection sit

No black box warning on record for Fulvestrant

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. ( 5.1 ) Increased Exposure in Patients with Hepatic Impairment: Use a 250 mg dose for patients with moderate hepatic impairment. ( 2.2 , 5.2 , 8.6 ) Injection Site Reaction: Use caution while administering Fulvestrant Injection at the dorsogluteal injection sit

Fulvestrant Black Box Warning

No black box warning on record for Fulvestrant

Other warnings & precautions

Fulvestrant Black Box Warning

No black box warning on record for Fulvestrant

Other warnings & precautions